[Articles] Estimated effect of correcting inequalities in minimally invasive surgical resection in patients with colon cancer in England: a population-based study Correcting inequalities in implementation of minimally invasive surgical resection has the potential to reduce inequalities in colon cancer outcomes. The Lancet Oncology February 28, 2026 Original source
[Articles] Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial Pembrolizumab plus lenvatinib showed promising anti-tumour activity and manageable safety in patients with recurrent CCGC, including in patients with disease progression following previous treatment with anti-angiogenic therapy. These findings support further evaluation of this combination in randomised controlled trials. The Lancet Oncology February 28, 2026 Original source
[Articles] Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study Progression-free status at 24 months was a strong prognostic marker for overall survival at the patient level in HPV-positive oropharyngeal cancer and future trial-level analysis is now warranted. The adoption of this endpoint has the potential to accelerate therapeutic development by enabling earlier evaluation of treatment activity, thereby facilitating the timely introduction of novel therapies to this patient population before… The Lancet Oncology February 28, 2026 Original source
[Articles] Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration WOLVERINE showed a benefit with MDT for oligometastatic prostate cancer in progression-free survival, radiological progression-free survival, and castration resistance-free survival. Overall survival benefit was not significant and further research is needed. The Lancet Oncology February 28, 2026 Original source
[Articles] O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma. Thus, CE-T1MRI remains the preferred delineation method in this setting. The Lancet Oncology February 28, 2026 Original source
[Articles] Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial Aumolertinib showed substantial clinical benefits as adjuvant therapy in Chinese patients with stage II–IIIB EGFR-mutated NSCLC. The manageable safety profile of aumolertinib supports its suitability in the adjuvant setting. The Lancet Oncology February 28, 2026 Original source
[Perspectives] Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment Dirk De Ruysscher, *Pim J J Damen The Lancet Oncology February 28, 2026 Original source
[News] US EPA to stop calculating lives saved by air pollution control Under the Trump Administration, the US Environmental Protection Agency (EPA) plans to stop considering the lives and money saved by controlling air pollution caused by two pollutants—fine particulate matter (PM2·5) and ozone—while setting clean-air rules. According to the plan, instead of calculating the monetary value of saving human lives, EPA will focus only on the cost to the industry while… The Lancet Oncology February 28, 2026 Original source
[News] WHO on global taxation of alcoholic and sugar-sweetened drinks WHO is calling on governments to raise taxes on alcoholic beverages and sugary drinks after two new reports show both have become cheaper over the past few years. National tax policies should ensure these unhealthy products become less affordable over time, highlights WHO. However, the reports released on Jan 13, 2026, reveal that only 37 countries have achieved this trend… The Lancet Oncology February 28, 2026 Original source
[News] PFAS in biosolids used in US food supply could pose cancer risk Almost 70 million acres of US farmland might be contaminated with cancer-causing perfluoroalkyl and polyfluoroalkyl substances (PFASs), according to estimates from biosolids industry groups. The Lancet Oncology February 28, 2026 Original source
[News] Progress in global tobacco control measures Global tobacco control measures have led to substantial decrease in the number of tobacco users—from 1·38 billion in 2000 to 1·20 billion in 2024, but there are concerns over possible undermining of these measures in some countries, due to untoward activities including illicit tobacco trade and interference of the tobacco industry in policy making. The Lancet Oncology February 28, 2026 Original source
[News] Donated sperm with TP53 mutation used to conceive at least 197 children Sperm from an otherwise healthy sperm donor—some of which harboured the TP53 gene mutation that causes a 90% lifetime cancer risk due to development of Li Fraumeni syndrome if passed to conceived children—has been used to father at least 197 children across Europe. Some of these children have already died from various cancers, and others have developed one or more… The Lancet Oncology February 28, 2026 Original source
[News] San Antonio Breast Cancer Symposium 2025 In the phase 3 IidERA trial presented by Aditya Bardia (University of California Los Angeles, Los Angeles, CA, USA), adjuvant giredestrant, an oral selective oestrogen receptor degrader (SERD) showed significant improvement in invasive disease-free survival (iDFS) compared with standard-of-care endocrine therapy in patients with early-stage HR+ HER2– breast cancer. 4170 patients were randomly assigned (1:1) to receive either 30 mg… The Lancet Oncology February 28, 2026 Original source
[Corrections] Correction to Lancet Oncol 2026; 27: 90–102 Sun J-M, Chao Y, Kim S-B, et al. First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. Lancet Oncol 2026; 27: 90–102—This Article was published with the incorrect appendix file. The file has been corrected as of Feb 2, 2026. The Lancet Oncology February 28, 2026 Original source
[Corrections] Correction to Lancet Oncol 2026; 27: 11–12 Cattley RC, De Roos AJ, Mandrioli D, et al. Carcinogenicity of atrazine, alachlor, and vinclozolin. Lancet Oncol 2026; 27: 11–12—In this News, the meta-odds ratio in the second sentence of the fifth paragraph should have been 1·99; 95% CI 1·13–3·53. This correction has been made to the online version as of Feb 2, 2026. The Lancet Oncology February 28, 2026 Original source
[Correspondence] Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma – Authors' reply We thank Bhumesh Tyagi and colleagues for their comments. INTERACT-ION was designed to show the feasibility and preliminary efficacy of induction with modified docetaxel, cisplatin, and fluorouracil (mDCF) plus ezabenlimab then intensity-modulated radiotherapy with involved-node chemoradiotherapy (INRT) in patients with locally advanced squamous cell anal carcinoma (SCAC).1 We showed the value of this novel induction regimen, with 38 (75%) of… The Lancet Oncology February 28, 2026 Original source
[Correspondence] Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma Stefano Kim and colleagues1 report promising activity from a combined neoadjuvant strategy using ezabenlimab (an anti-PD-1) with modified docetaxel, cisplatin, and fluorouracil (mDCF) followed by personalised intensity-modulated radiotherapy with involved-node chemoradiotherapy (INRT) in patients with stage 3 squamous cell anal carcinoma (SCAC). In this phase 2 trial, Kim and colleagues showed high rates of pathological (41 [84%] of 49 evaluable… The Lancet Oncology February 28, 2026 Original source
[Correspondence] Inverse care law and inequity of access to patient-centric care In 1971, Julian Tudor Hart wrote that “the availability of good medical care tends to vary inversely with the need of the population served”.1 Amid extraordinary progress in precision therapy, a quieter crisis has emerged viz the loss of the human face of cancer care. The Lancet Oncology Commission from Gary Rodin and colleagues on the human crisis in cancer2… The Lancet Oncology February 28, 2026 Original source
[Correspondence] Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply We were surprised to read the letter from David J Stewart and colleagues in response to our Comment because they dismiss overall survival—the endpoint that patients have consistently reported as most meaningful1—as difficult and unreliable. We agree that measuring overall survival is difficult, but that cannot be an excuse to not measure it. We disagree that overall survival is unreliable.… The Lancet Oncology February 28, 2026 Original source
[Correspondence] Factors that can make overall survival unreliable as a clinical trial outcome Samual X Stevens and colleagues advocate overall survival as the decisive trial endpoint.1 The authors overstate their case in saying that, “Oncology literature abounds with examples where reliance on putative surrogate endpoints has resulted in increased deaths.” They note that immunotherapy decreased myeloma overall survival, but the implication that surrogate endpoints suggested immunotherapy benefit was incorrect. Neither response rates nor… The Lancet Oncology February 28, 2026 Original source